232 related articles for article (PubMed ID: 17164136)
21. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.
Haag MD; Bos MJ; Hofman A; Koudstaal PJ; Breteler MM; Stricker BH
Arch Intern Med; 2008 Jun; 168(11):1219-24. PubMed ID: 18541831
[TBL] [Abstract][Full Text] [Related]
22. Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib.
Giraudel JM; Toutain PL; King JN; Lees P
J Vet Pharmacol Ther; 2009 Feb; 32(1):31-40. PubMed ID: 19161453
[TBL] [Abstract][Full Text] [Related]
23. Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects.
Ushiyama S; Yamada T; Murakami Y; Kumakura S; Inoue S; Suzuki K; Nakao A; Kawara A; Kimura T
Eur J Pharmacol; 2008 Jan; 578(1):76-86. PubMed ID: 17920584
[TBL] [Abstract][Full Text] [Related]
24. New insights into COX-2 biology and inhibition.
Patrignani P; Tacconelli S; Sciulli MG; Capone ML
Brain Res Brain Res Rev; 2005 Apr; 48(2):352-9. PubMed ID: 15850674
[TBL] [Abstract][Full Text] [Related]
25. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
[TBL] [Abstract][Full Text] [Related]
26. In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study.
Schmid VB; Seewald W; Lees P; King JN
J Vet Pharmacol Ther; 2010 Oct; 33(5):444-52. PubMed ID: 20840388
[TBL] [Abstract][Full Text] [Related]
27. Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases.
Li H; Hortmann M; Daiber A; Oelze M; Ostad MA; Schwarz PM; Xu H; Xia N; Kleschyov AL; Mang C; Warnholtz A; Münzel T; Förstermann U
J Pharmacol Exp Ther; 2008 Sep; 326(3):745-53. PubMed ID: 18550689
[TBL] [Abstract][Full Text] [Related]
28. Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2-COX-1 selectivity on urinary sodium and potassium excretion in the rat.
Harirforoosh S; Jamali F
Can J Physiol Pharmacol; 2005 Jan; 83(1):85-90. PubMed ID: 15759054
[TBL] [Abstract][Full Text] [Related]
29. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat.
Wallace JL; Caliendo G; Santagada V; Cirino G; Fiorucci S
Gastroenterology; 2007 Jan; 132(1):261-71. PubMed ID: 17241876
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors.
Huntjens DR; Danhof M; Della Pasqua OE
Rheumatology (Oxford); 2005 Jul; 44(7):846-59. PubMed ID: 15855183
[TBL] [Abstract][Full Text] [Related]
31. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
32. Perspective assessment of COX-1 and COX-2 selectivity of nonsteroidal anti-inflammatory drugs from clinical practice: use of genetic function approximation.
Zambre AP; Ganure AL; Shinde DB; Kulkarni VM
J Chem Inf Model; 2007; 47(2):635-43. PubMed ID: 17256838
[TBL] [Abstract][Full Text] [Related]
33. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
Patterson MK; Castellsague J; Walker AM
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
[TBL] [Abstract][Full Text] [Related]
34. Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?
Brune K; Furst DE
Rheumatology (Oxford); 2007 Jun; 46(6):911-9. PubMed ID: 17459958
[TBL] [Abstract][Full Text] [Related]
35. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.
Martelli A; Testai L; Anzini M; Cappelli A; Di Capua A; Biava M; Poce G; Consalvi S; Giordani A; Caselli G; Rovati L; Ghelardini C; Patrignani P; Sautebin L; Breschi MC; Calderone V
Pharmacol Res; 2013 Dec; 78():1-9. PubMed ID: 24083950
[TBL] [Abstract][Full Text] [Related]
36. [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain].
Bijlsma JW; Lems WF; van de Laar MA
Ned Tijdschr Geneeskd; 2007 Apr; 151(14):795-8. PubMed ID: 17469317
[TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacology of novel selective COX-2 inhibitors.
Tacconelli S; Capone ML; Patrignani P
Curr Pharm Des; 2004; 10(6):589-601. PubMed ID: 14965322
[TBL] [Abstract][Full Text] [Related]
38. Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition.
Klein T; Eltze M; Grebe T; Hatzelmann A; Kömhoff M
Cardiovasc Res; 2007 Jul; 75(2):390-7. PubMed ID: 17383621
[TBL] [Abstract][Full Text] [Related]
39. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
40. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon.
Fiorucci S; Santucci L; Distrutti E
Dig Liver Dis; 2007 Dec; 39(12):1043-51. PubMed ID: 17997373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
